Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Idogen AB (publ) announces today that the company has received approval from the Norwegian REK (Regionale komiteer for medicinsk og helsefaglig forskningetikk) in Oslo to conduct the clinical phase I/IIa study of their drug candidate within the IDO 8 program for patients suffering from hemophilia who have developed antibodies against their life-saving factor VIII treatment. The approval means that study activities can begin at the clinic and that the first patient can be enrolled in the study within short.
Idogen has now received approval from the ethics committee in Oslo to conduct the company's phase I/IIa study in hemophilia with the drug candidate, ItolDC-028. The study is conducted under the leadership of professor and senor physician Pål Andre Holme. Shortly, the first patient will be able to be enrolled, after which the first step in the treatment will be possible to be carried out.
"After intensive preparations and great commitment at our Norwegian trial center, we are now ready to start recruiting patients for the phase I/II study of our first drug candidate, ItolDC-028. The step into clinical phase is the most important milestone so far in the development of our unique cell therapy, to develop a product that can treat or prevent the development of antibodies against the important treatment with coagulation factor VIII (FVIII)", says Hanjing Xie, CMO of Idogen.
For further information, please contact:
Christina Herder, acting CEO, Idogen AB
Phone: +46 7037 47 156
Email: christina.herder@idogen.com
Certified Advisor:
Vator Securities AB.
The information was submitted for publication, through the agency of the contact persons set out above, on 21 September, 2022,at 08:02 CET.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.